Compare Nuwellis Inc (NUWE) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Starbucks Corp — how do they compare? Nuwellis Inc trades at $0.8 (market cap $2.50M), while Starbucks Corp trades at $100.52 (market cap $116.29B). The key difference: Starbucks Corp is far larger — about 46516× Nuwellis Inc's market cap, and Starbucks Corp pays a 2.43% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | SBUX | |
|---|---|---|
Market Cap | $2.50M | $116.29B |
Sector | Technology | Consumer Cyclical |
52-Week High | $164.50 | $108.55 |
52-Week Low | $0.73 | $78.46 |
Enterprise Value | -$1.21M | $135.12B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
Starbucks (SBUX) trades at $102.01, down 2.35% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish momentum in moving averages but recent earnings beats in Q1 and Q2 2026 highlight operational progress. Revenue reached $37.18B in 2025, though net income margin compressed to 5.17%. Analyst consensus is a Buy with a $113.60 price target, but high P/E of 58.97 suggests premium valuation. Recent news emphasizes CEO Niccol's turnaround efforts and union-related legal developments.
The outlook balances earnings momentum against valuation concerns. Upside hinges on margin recovery and sustained comp sales growth, but risks include labor disputes, high debt, and competitive pressures. Institutional sentiment is cautiously optimistic, with 47.46% of analysts rating Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
